<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="75426"><DrugName>buprenorphine hydrochloride (oral, formulated with abuse-deterrent naloxone), Reckitt Benckiser</DrugName><DrugNamesKey><Name id="42970135">Suboxone</Name><Name id="42753853">buprenorphine hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>buprenorphine hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>buprenorphine hydrochloride (oral, formulated with abuse-deterrent naloxone), Reckitt Benckiser</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Suboxone</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>52485-79-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>465-65-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>53152-21-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29074">Reckitt Benckiser plc</CompanyOriginator><CompaniesPrimary><Company id="1082975">Indivior plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company><Company id="19711">Schering-Plough Corp</Company><Company id="29074">Reckitt Benckiser plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="75426" type="Drug"><TargetEntity id="320797" type="siDrug">Buprenorphine/Naloxone</TargetEntity></SourceEntity><SourceEntity id="1082975" type="Company"><TargetEntity id="5044066242" type="organizationId">Indivior PLC</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="29074" type="Company"><TargetEntity id="5000008313" type="organizationId">Reckitt Benckiser PLC</TargetEntity></SourceEntity><SourceEntity id="243" type="ciIndication"><TargetEntity id="F11.2" type="ICD10"></TargetEntity><TargetEntity id="D009293" type="MeSH"></TargetEntity><TargetEntity id="-1731206897" type="omicsDisease"></TargetEntity><TargetEntity id="1154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="292" type="Action"><TargetEntity id="269" type="Mechanism">kappa-Opioid Antagonists</TargetEntity></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity><SourceEntity id="PTGT-01193" type="ciTarget"><TargetEntity id="65128967849863" type="siTarget">Kappa-type opioid receptor</TargetEntity><TargetEntity id="1010" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01361" type="ciTarget"><TargetEntity id="43836512449883" type="siTarget">Mu-type opioid receptor</TargetEntity><TargetEntity id="1032" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Opiate dependence - US - Jan-2003</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="243">Opiate dependence</Indication></IndicationsPrimary><ActionsPrimary><Action id="292">Opioid receptor kappa antagonist</Action><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="680">Buccal formulation systemic</Technology></Technologies><LastModificationDate>2019-06-20T05:48:22.000Z</LastModificationDate><ChangeDateLast>2019-04-10T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-12T04:25:33.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="19202" linkType="Company"&gt;Reckitt &amp;amp; Colman&lt;/ulink&gt; (then &lt;ulink linkID="29074" linkType="Company"&gt;Reckitt Benckiser&lt;/ulink&gt;, now &lt;ulink linkID="1082975" linkType="Company"&gt;Indivior&lt;/ulink&gt;) Suboxone is an abuse-deterrent formulation of the partial mu opioid agonist &lt;ulink linkID="2695" linkType="Drug"&gt;buprenorphine hydrochloride&lt;/ulink&gt; in  sublingual tablet and  sublingual film formulations that release the opioid antagonist naloxone if crushed for injection. The sublingual film version is indicated in the US for the treatment of opioid dependence; as maintenance therapy and for induction therapy in patients dependent on short-acting opioid products who are in withdrawal. The sublingual tablet version is indicated in the EU as a substitution treatment for opioid dependence  in adults and adolescents over 15 years of age who have agreed to be treated for addiction [&lt;ulink linkID="1253334" linkType="Reference"&gt;1253334&lt;/ulink&gt;], [&lt;ulink linkID="1253345" linkType="Reference"&gt;1253345&lt;/ulink&gt;], [&lt;ulink linkID="1253564" linkType="Reference"&gt;1253564&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Suboxone sublingual tablets were launched in the US in January 2003 [&lt;ulink linkID="1253294" linkType="Reference"&gt;1253294&lt;/ulink&gt;], however in September 2012, the company voluntarily discontinued distribution of Suboxone tablets in the US after concerns were raised regarding pediatric exposure. Patients taking Suboxone tablets would be transitioned to Suboxone sublingual film from March 2013 [&lt;ulink linkID="1326331" linkType="Reference"&gt;1326331&lt;/ulink&gt;], [&lt;ulink linkID="1326332" linkType="Reference"&gt;1326332&lt;/ulink&gt;], [&lt;ulink linkID="1385228" linkType="Reference"&gt;1385228&lt;/ulink&gt;]. In September 2006, Suboxone tablets were  approved in the EU for opioid dependence [&lt;ulink linkID="728533" linkType="Reference"&gt;728533&lt;/ulink&gt;], [&lt;ulink linkID="1253345" linkType="Reference"&gt;1253345&lt;/ulink&gt;]; by  November 2007, the product had been launched in the EU [&lt;ulink linkID="1253962" linkType="Reference"&gt;1253962&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The sublingual film formulation, which utilizes PharmFilm technology from MonoSol Rx (now &lt;ulink linkID="1008765" linkType="Company"&gt;Aquestive Therapeutics&lt;/ulink&gt;), was approved in the US in August 2010; the product was intended to improve the time to dissolve and the taste [&lt;ulink linkID="1127452" linkType="Reference"&gt;1127452&lt;/ulink&gt;],  [&lt;ulink linkID="1253564" linkType="Reference"&gt;1253564&lt;/ulink&gt;]. In August 2012, the FDA approved additional dosages of Suboxone sublingual film at 4 and 12 mg; the new dosages would be available in the US later that year [&lt;ulink linkID="1316740" linkType="Reference"&gt;1316740&lt;/ulink&gt;].  By March 2015, Indivior was preparing for a potential launch of the film version in Europe [&lt;ulink linkID="1650527" linkType="Reference"&gt;1650527&lt;/ulink&gt;], however this had been delayed by March 2016 as the prototype formulation for the EU had not met its specified bio-equivalency to the EU-approved Suboxone Tablet [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;];  in March 2018, the film formulation was not listed as launched  in Europe [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].  By March 2018, Indivior had been developed a Suboxone film reformulation; however, at that time, the company noted that the reformulation did not advance [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;A &lt;ulink linkID="83478" linkType="Drug"&gt;once-monthly depot formulation of Suboxone&lt;/ulink&gt; is also under development. Indivior also markets &lt;ulink linkID="2695" linkType="Drug"&gt;buprenorphine&lt;/ulink&gt;, which was previously available as the analgesic Temgesic/Buprenex and is now marketed as a sublingual tablet formulation (Subutex) for the treatment of opioid dependence [&lt;ulink linkID="363364" linkType="reference"&gt;363364&lt;/ulink&gt;], [&lt;ulink linkID="1079416" linkType="Reference"&gt;1079416&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;Sublingual tablets&lt;/subtitle&gt;US exclusivity on the sublingual tablet expired in 2009 [&lt;ulink linkID="953672" linkType="Reference"&gt;953672&lt;/ulink&gt;]. Exclusivity in the EU was expected to expire in 2016 [&lt;ulink linkID="1253294" linkType="Reference"&gt;1253294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016,  &lt;ulink linkID="1028289" linkType="Company"&gt;Lannett&lt;/ulink&gt;'s ANDA for its generic version of buprenorphine hydrochloride with naloxone sublingual tablets (2 mg/0.5 mg and 8 mg/2 mg) was granted FDA approval in the US [&lt;ulink linkID="1797715" linkType="Reference"&gt;1797715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the end of 2015, a generic tablet version from &lt;ulink linkID="28817" linkType="Company"&gt;Akorn&lt;/ulink&gt; (formerly Hi-Tech) entered the market  [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, &lt;ulink linkID="1027030" linkType="Company"&gt;Amneal Pharmaceuticals&lt;/ulink&gt; was granted FDA approval for its generic version of buprenorphine hydrochloride with naloxone sublingual tablets; Amneal began immediate shipment of the product, which would be available in 2 mg/0.5 mg and 8 mg/2 mg dosages [&lt;ulink linkID="1386008" linkType="Reference"&gt;1386008&lt;/ulink&gt;]. In August 2013, &lt;ulink linkID="17129" linkType="Company"&gt;Mallinckrodt&lt;/ulink&gt; agreed to distribute Amneal's generic to addiction centers [&lt;ulink linkID="1467440" linkType="Reference"&gt;1467440&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in February 2013, &lt;ulink linkID="21717" linkType="Company"&gt;Actavis&lt;/ulink&gt; received FDA approval for its generic buprenorphine hydrochloride with naloxone tablets (2 mg/0.5 mg and 8 mg/2 mg); Actavis began shipment of the product immediately [&lt;ulink linkID="1385937" linkType="Reference"&gt;1385937&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Sublingual film&lt;/subtitle&gt;Three constraining formulation patents for Suboxone sublingual film are listed in the Orange Book, &lt;ulink linkID="PA3701491" linkType="Patent"&gt;US-08017150&lt;/ulink&gt;, &lt;ulink linkID="PA3606172" linkType="Patent"&gt;US-08603514&lt;/ulink&gt; and &lt;ulink linkID="PA6345423" linkType="Patent"&gt;US-08475832&lt;/ulink&gt;,  with expirations of February  2023, April  2024 and March  2030, respectively [&lt;ulink linkID="1700351" linkType="Reference"&gt;1700351&lt;/ulink&gt;]. By July 2015, the USPTO's Patent Trial and Appeal Board (PTAB) had decided to conduct an inter partes review regarding  US-08475832 for the sublingual film formulation. Of the 19 total claims in the '832 patent, only five claims were challenged in the ANDA litigation against manufacturers seeking approval to market generic Suboxone, and the PTAB held that those five claims had been shown to be unpatentable over certain prior art; Individior appealed the decision [&lt;ulink linkID="1674591" linkType="Reference"&gt;1674591&lt;/ulink&gt;]. Indivior's opening brief was filed in January 2016 [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]. In June 2016, the Court found the asserted claims of  US-08475832  invalid [&lt;ulink linkID="1769383" linkType="Reference"&gt;1769383&lt;/ulink&gt;]. In June 2017, &lt;ulink linkID="PA8640863" linkType="Patent"&gt;US-09687454&lt;/ulink&gt; was issued, and listed in the FDA's Orange Book relating to an oral film containing buprenorphine and naloxone [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December  2016, &lt;ulink linkID="1061689" linkType="Company"&gt;Rhodes Pharmaceuticals&lt;/ulink&gt; filed a complaint against Indivior alleging that Indivior's sale of Suboxone film in the US infringed one or more claims of a patent issued in June 2016 (the  application of which was filed in August 2007) In March 2018, Indivior believed this claim was without merit and was to continue to vigorously defend this action [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2015, Indivior received a Paragraph IV notification from &lt;ulink linkID="23137" linkType="Company"&gt;Sandoz&lt;/ulink&gt; stating that it had filed an ANDA seeking approval to market a generic version of the drug before the expiration of Indivior's three Orange Book listed patents (US-08017150, US-08603514 and US-08475832) for Suboxone sublingual film. At that time, Indivior stated that intended to initiate a patent infringement lawsuit against Sandoz [&lt;ulink linkID="1700351" linkType="Reference"&gt;1700351&lt;/ulink&gt;]. As of March 2016, trial against Sandoz in the lawsuit involving the Orange Book-listed patents was scheduled for September 2017, with Sandoz's stay expiring in April 2018 [&lt;ulink linkID="1760222" linkType="Reference"&gt;1760222&lt;/ulink&gt;]. In August 2016, litigation against Sandoz was dismissed as Sandoz was no longer pursuing Paragraph IV certifications for its proposed generic [&lt;ulink linkID="1897303" linkType="Reference"&gt;1897303&lt;/ulink&gt;]. In February 2019, Sandoz launched its generic version; the product was an authorized generic on behalf of Indivior [&lt;ulink linkID="2120906" linkType="Reference"&gt;2120906&lt;/ulink&gt;], [&lt;ulink linkID="2121112" linkType="Reference"&gt;2121112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, Indivior received a Paragraph IV notification from &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; stating that it had filed an ANDA seeking approval to market a generic version of the drug before the expiration of Indivior's three Orange Book listed patents. The company  planned to initiate a patent infringement lawsuit  [&lt;ulink linkID="1760222" linkType="Reference"&gt;1760222&lt;/ulink&gt;]. As of March 2016, trial against Mylan in the lawsuit involving the Orange Book-listed patents was scheduled for September 2017, with Mylan’s stay expiring in March 2018 [&lt;ulink linkID="1760222" linkType="Reference"&gt;1760222&lt;/ulink&gt;]. In September 2017, Indivior filed a US lawsuit against Mylan alleging patent infringement of US-09687454 [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;]. Later that month, Indivor and Mylan entered into a settlement agreement, the terms of which were not disclosed [&lt;ulink linkID="1964210" linkType="Reference"&gt;1964210&lt;/ulink&gt;]. In June 2018, the FDA approved Mylan's generic version of the sublingual film formulation of the drug [&lt;ulink linkID="2044843" linkType="Reference"&gt;2044843&lt;/ulink&gt;]. In February 2019, Mylan launched its generic  8 mg/2 mg and 12 mg/3 mg buprenorphine/naloxone sublingual film products [&lt;ulink linkID="2122341" linkType="Reference"&gt;2122341&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt; provided Indivior with two Paragraph IV notices following the filing of two ANDAs to market a generic equivalent of Suboxone Film. In December 2014, Indivior filed suit against Teva asserting three Orange Book-listed patents and two process patents. In October 2015,  Indivior was granted a motion to amend its complaint to specifically refer to  one of the two ANDAs [&lt;ulink linkID="1702199" linkType="Reference"&gt;1702199&lt;/ulink&gt;].  In August 2016,  &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy&lt;/ulink&gt;'s acquired both of Teva's ANDAs; the ANDAs were divested by Teva as a precondition to its acquisition of &lt;ulink linkID="1088700" linkType="Company"&gt;Allergan&lt;/ulink&gt;'s generics business. Dr Reddy's  was subsituted as the defendent in the trial, which commenced in November 2016 [&lt;ulink linkID="1897330" linkType="Reference"&gt;1897330&lt;/ulink&gt;], [&lt;ulink linkID="1897303" linkType="Reference"&gt;1897303&lt;/ulink&gt;], [&lt;ulink linkID="1785384" linkType="Reference"&gt;1785384&lt;/ulink&gt;]. By May 2017, Dr Reddy's had received a CRL from the FDA regarding  the ANDA for its generic Suboxone [&lt;ulink linkID="1928692" linkType="Reference"&gt;1928692&lt;/ulink&gt;]. By July 2017, Dr Reddy's had responded to the CRL; at that time, the company expected a judgement from the patent litigation within 8 weeks  [&lt;ulink linkID="1948966" linkType="Reference"&gt;1948966&lt;/ulink&gt;]. In September 2017, Indivior was preparing an appeal against a decision in the lawsuit against Dr Reddy's and expected to file with the US Court of Appeals for the Federal Circuit. At that time, Indivior had also filed US lawsuits against Dr Reddy's and Teva alleging patent infringement of US-09687454 [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;]. In November 2017, trials against Dr Reddy's, Actavis and Par took place regarding &lt;ulink linkID="PA7623274" linkType="Patent"&gt;US-08900497&lt;/ulink&gt;, and a trial against Dr Reddy's regarding US-08017150 and US-08603514. The rulings found the asserted claims were valid but not infringed. Indivior appealed the rulings [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. By February 2018, Indivior had filed against Dr Reddy's, Par and Teva regarding US-09687454. At that time, Indivior filed suit against Dr Reddy's, Par and Teva regarding infringement of &lt;ulink linkID="PA9479073" linkType="Patent"&gt;US-09855221&lt;/ulink&gt; [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. In April 2018, Indivior filed patent lawsuits against Dr Reddy's and Teva for infringement of &lt;ulink linkID="PA9567202" linkType="Patent"&gt;US-09931305&lt;/ulink&gt; in their respective generic versions of suboxone sublingual film [&lt;ulink linkID="2019740" linkType="Reference"&gt;2019740&lt;/ulink&gt;]. In June 2018, the FDA approved Dr Reddy's' generic version of the sublingual film formulation of the drug; the generic was launched immediately [&lt;ulink linkID="2044843" linkType="Reference"&gt;2044843&lt;/ulink&gt;], [&lt;ulink linkID="2044970" linkType="Reference"&gt;2044970&lt;/ulink&gt;]. By June 2018, the District Court had received and reviewed an emergency application from Indivior for a temporary restraining order and preliminary injunction against Dr. Reddy's involving US-09931305. At that time, the court  issued a temporary restraining order   against the company  with respect to further sales and commercialization pending a hearing and decision on the injunction application, with commercial manufacturing  unaffected by the ruling. The court  scheduled an expedited  hearing for June 28, 2018; a ruling was expected soon after [&lt;ulink linkID="2045423" linkType="Reference"&gt;2045423&lt;/ulink&gt;], [&lt;ulink linkID="2045270" linkType="Reference"&gt;2045270&lt;/ulink&gt;]. Also by June 2018, Indivior had appealed the finding of non-infringement of patent US-08603514 [&lt;ulink linkID="2045270" linkType="Reference"&gt;2045270&lt;/ulink&gt;]. In July 2018, the US Court of Appeals for the Federal Circuit (CAFC) granted a preliminary injunction against Dr Reddy's [&lt;ulink linkID="2096938" linkType="Reference"&gt;2096938&lt;/ulink&gt;]. In November 2018, the US CAFC overturned the preliminary injunction against Dr Reddy's. At that time, Indivior assumed that Dr Reddy's would resume the launch of its generic sublingual film product in the US on an 'at-risk' basis, following the mandate from the CAFC, subject to the outcome of the appeal of the non-infringement judgements related to the two US patents, US-08603514 and US-08017150, as well as ongoing litigation in the District of New Jersey regarding recently-granted Orange Book listed patents, such as US-09931305. Indivior planned to file a petition for both panel rehearing and rehearing en banc of the ruling which vacated the preliminary injunction, following the motion issued by Dr Reddy's which requested that the mandate be immediately issued, or to stay the preliminary injunction pending issuance of the mandate. At that time, Indivior announced they would continue to pursue ongoing patent infringement cases against Dr Reddy's. [&lt;ulink linkID="2096762" linkType="Reference"&gt;2096762&lt;/ulink&gt;], [&lt;ulink linkID="2096934" linkType="Reference"&gt;2096934&lt;/ulink&gt;], [&lt;ulink linkID="2096938" linkType="Reference"&gt;2096938&lt;/ulink&gt;], [&lt;ulink linkID="2096941" linkType="Reference"&gt;2096941&lt;/ulink&gt;]. In November 2018, the US appeals granted Dr Reddy permission to sell its generic. In December 2018, the US CAFC denied Dr Reddy's motion to immediately issue the mandate following the CAFC's and the preliminary injunction against Dr Reddy would remain in place. At that time, Indivior planned to file petition for rehearing and rehearing en banc by December 20, 2018 [&lt;ulink linkID="2103362" linkType="Reference"&gt;2103362&lt;/ulink&gt;], [&lt;ulink linkID="2103360" linkType="Reference"&gt;2103360&lt;/ulink&gt;]. In February 2019, following the decsion from the Federal Circuit coming into effect on the 19th of February, Dr Reddy re-launched its generic version of the drug (2 / 0.5 mg, 4 /1 mg, 8 /2mg and 12 / 3 mg) [&lt;ulink linkID="2121645" linkType="Reference"&gt;2121645&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2014, an ANDA had been filed by &lt;ulink linkID="26171" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="1051273" linkType="Company"&gt;Alvogen&lt;/ulink&gt;; Reckitt had filed suit against the company [&lt;ulink linkID="1547350" linkType="Reference"&gt;1547350&lt;/ulink&gt;]. As of March 2016, trial against Alvogen was scheduled for April 2017, with Alvogen's 30-month stay of FDA approval expiring in October 2017 [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]. By December 2016, the trial had been postponed to September 2017 [&lt;ulink linkID="1897303" linkType="Reference"&gt;1897303&lt;/ulink&gt;]. In September 2017, a trial against Alvogen regarding US-08603514 and US-08900497 took place. Alvogen agreed not to launch until March 29, 2018 or until it received a favorable ruling from the District Court [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. In September 2017, Indivior filed a US lawsuit against Alvogen  alleging  infringement of US-09687454 [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;].   In February 2018, Indivior filed suit against Alvogen regarding infringement of US-09855221 [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;].  In March 2018, the US District Court ruled that Alvogen's generic did not infringe US-08603514 and US-08900497. Alvogen would proceed with ANDA-related preparations after the decision [&lt;ulink linkID="2019540" linkType="Reference"&gt;2019540&lt;/ulink&gt;]. In April 2018, Indivior filed patent lawsuits against Alvogen for infringement of US-09931305 in its generic versions of the sublingual film [&lt;ulink linkID="2019740" linkType="Reference"&gt;2019740&lt;/ulink&gt;]. In January 2019,  Alvogen's buprenorphine/naloxone sublingual film products were approved by the FDA [&lt;ulink linkID="2122517" linkType="Reference"&gt;2122517&lt;/ulink&gt;]. Later that month, the US District Court granted a temporary restraining order preventing Alvogen from launching its generic version of the sublingual film. The order would be in force until February 07, 2019, on which day a preliminary injunction hearing was planned. At that time, Indivior was also pursuing its appeal of the US District Court non-infringement decision regarding US-08603514 [&lt;ulink linkID="2113893" linkType="Reference"&gt;2113893&lt;/ulink&gt;], [&lt;ulink linkID="2114024" linkType="Reference"&gt;2114024&lt;/ulink&gt;]. In February 2019, Indivior entered into an agreement with Alvogen enjoining the company from selling its generic buprenorphine and naloxone sublingual film product in the US until the US CAFC issued a mandate vacating the preliminary injunction against Dr Reddy's previously granted by the US District Court  on July 13, 2018.  As a result of the agreement, the preliminary injunction  hearing would not take place [&lt;ulink linkID="2116256" linkType="Reference"&gt;2116256&lt;/ulink&gt;]. Later in February 2019, Alvogen (subsequently &lt;ulink linkID="1052101" linkType="Company"&gt;Lotus&lt;/ulink&gt;) launched its generic version of the buprenorphine hydrochloride/naloxone hydrochloride sublingual film (2mg/0.5 mg, 4mg/1mg, 8 mg/2mg and 12 mg/3mg) [&lt;ulink linkID="2121275" linkType="Reference"&gt;2121275&lt;/ulink&gt;], [&lt;ulink linkID="2122517" linkType="Reference"&gt;2122517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, &lt;ulink linkID="21717" linkType="Company"&gt;Actavis&lt;/ulink&gt; submitted an ANDA for its generic version of sublingual film (2 mg/0.5 mg and 8 mg/2 mg) in the US; the company believed it was entitled to 180-day exclusivity as the first to file an ANDA. At that time, Reckitt Benckiser filed a  lawsuit against Actavis alleging patent infringement [&lt;ulink linkID="1485698" linkType="Reference"&gt;1485698&lt;/ulink&gt;]. Trial in the case took place in November 2015 [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]. In June 2016, a US District Court ruled against  Actavis concerning its ANDA litigation, determining that its generic version infringed the asserted claims of the Orange book-listed US-08603514, upholding its validity and enforceablity [&lt;ulink linkID="1769383" linkType="Reference"&gt;1769383&lt;/ulink&gt;]. In September 2017, Indivior filed a US lawsuit against Actavis alleging patent infringement of US-09687454 [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;]. In October 2017, Actavis received a tentative approval from the FDA for its 8 mg/2 mg product. However, under the previous ruling the company would be enjoined from launching its generic products until 2024 [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. In February 2018, Indivior filed suit against Actavis regarding infringement of US-9855221 [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. In April 2018, Indivior filed patent lawsuits against Actavis for infringement of US-09931305 in its generic versions of suboxone sublingual film [&lt;ulink linkID="2019740" linkType="Reference"&gt;2019740&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2013, &lt;ulink linkID="1030619" linkType="Company"&gt;IntelGenx Corp&lt;/ulink&gt; reported that an ANDA had been submitted to the FDA for a generic version of the sublingual film; the ANDA was filed by an undisclosed US codevelopment and commercialization partner  [&lt;ulink linkID="1454917" linkType="Reference"&gt;1454917&lt;/ulink&gt;]. In August 2013, the partner was disclosed as &lt;ulink linkID="28968" linkType="Company"&gt;Par Pharmaceutical&lt;/ulink&gt; [&lt;ulink linkID="1469878" linkType="Reference"&gt;1469878&lt;/ulink&gt;]. By April 2014, Reckitt had filed suit against Par [&lt;ulink linkID="1547350" linkType="Reference"&gt;1547350&lt;/ulink&gt;]. In July 2015, a  trial date was set for November 2015 [&lt;ulink linkID="1674590" linkType="Reference"&gt;1674590&lt;/ulink&gt;]. In June 2016, a US District Court ruled against  Par, determining that its generic version infringed the asserted claims of the Orange book-listed US-08603514, upholding the validity and enforceablity. Additionally, the Court ruled that the asserted claims of US-08017150 were valid, but not infringed by Par's generic version  [&lt;ulink linkID="1769383" linkType="Reference"&gt;1769383&lt;/ulink&gt;]. Par had appealed the decision by December 2016 [&lt;ulink linkID="1897303" linkType="Reference"&gt;1897303&lt;/ulink&gt;]. In September 2017, Indivior filed a US lawsuit against Par alleging patent infringement of US-09687454 [&lt;ulink linkID="1962526" linkType="Reference"&gt;1962526&lt;/ulink&gt;]. In April 2018, Indivior filed patent lawsuits against Par for infringement of US-09931305 in its generic versions of suboxone sublingual film [&lt;ulink linkID="2019740" linkType="Reference"&gt;2019740&lt;/ulink&gt;]. In May 2018, Indivior entered into a settlement agreement with Par and IntelGenx to resolve pending patent litigations. The settlement allowed Par to begin selling its generic version of buprenorphine hydrochloride sublingual film in January 2023 or earlier under certain circumstances. Additonal terms of the agreement were confidential [&lt;ulink linkID="2033264" linkType="Reference"&gt;2033264&lt;/ulink&gt;], [&lt;ulink linkID="2035972" linkType="Reference"&gt;2035972&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2010, Suboxone sublingual film formulation was approved in the US for the treatment of opioid dependence [&lt;ulink linkID="1127452" linkType="Reference"&gt;1127452&lt;/ulink&gt;], [&lt;ulink linkID="1253564" linkType="Reference"&gt;1253564&lt;/ulink&gt;].  In August 2012, the product was approved at additional dosages of 4 and 12 mg in the US; the new dosages would be available later that year [&lt;ulink linkID="1316740" linkType="Reference"&gt;1316740&lt;/ulink&gt;]. In September 2015, the FDA approved the buccal route of administration for Suboxone film, allowing patients to choose either sublingual administration or against the cheek [&lt;ulink linkID="1735695" linkType="Reference"&gt;1735695&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1999, the buprenorphine plus naloxone combination had been granted Orphan Drug status in the US [&lt;ulink linkID="337499" linkType="Reference"&gt;337499&lt;/ulink&gt;]. In June 1999, the FDA received Reckitt's NDA for  the combination as a treatment for heroin addiction [&lt;ulink linkID="319526" linkType="Reference"&gt;319526&lt;/ulink&gt;], [&lt;ulink linkID="337499" linkType="Reference"&gt;337499&lt;/ulink&gt;], [&lt;ulink linkID="1253322" linkType="Reference"&gt;1253322&lt;/ulink&gt;]. In August 2002, the FDA approved Suboxone tablets for the treatment of opiate addiction [&lt;ulink linkID="466281" linkType="Reference"&gt;466281&lt;/ulink&gt;], [&lt;ulink linkID="1253317" linkType="Reference"&gt;1253317&lt;/ulink&gt;]. Suboxone tablets were launched in the US in January 2003 [&lt;ulink linkID="1253294" linkType="Reference"&gt;1253294&lt;/ulink&gt;]. However, in September 2012, Reckitt Benckiser notified the FDA that it would voluntarily discontinue the supply of Suboxone tablets in the US after concerns were raised regarding pediatric exposure. Patients taking Suboxone tablets would be transitioned to Suboxone sublingual film. At that time, the switch from the tablet formulation to the sublingual film formulation was expected to complete within the next 6 months [&lt;ulink linkID="1326331" linkType="Reference"&gt;1326331&lt;/ulink&gt;], [&lt;ulink linkID="1326332" linkType="Reference"&gt;1326332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;The EU CHMP recommended approval of Suboxone for the substitution treatment of opioid dependence in the EU in July 2006 [&lt;ulink linkID="680734" linkType="Reference"&gt;680734&lt;/ulink&gt;], [&lt;ulink linkID="680916" linkType="Reference"&gt;680916&lt;/ulink&gt;]. In September 2006, Suboxone sublingual tablets were approved in the EU  [&lt;ulink linkID="728533" linkType="Reference"&gt;728533&lt;/ulink&gt;], [&lt;ulink linkID="1253345" linkType="Reference"&gt;1253345&lt;/ulink&gt;];  by  November 2007, the product had been launched in the EU [&lt;ulink linkID="1253962" linkType="Reference"&gt;1253962&lt;/ulink&gt;]. The EU approved a new  16 mg/4 mg strength tablet version in November 2015 [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]. By March 2018, the tablet version had been launched in Austria, Croatia, Finland, Germany, Ireland, Italy, Latvia, Lithuania, Bosnia and Herzegovina, Estonia, Hungary, Poland, Romania, Slovenia,    Luxembourg, Malta, and the UK [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2015, Indivior was preparing for a potential launch of the film version in Europe [&lt;ulink linkID="1650527" linkType="Reference"&gt;1650527&lt;/ulink&gt;], however this had been delayed by March 2016 as the prototype formulation for the EU had not met its specified bio-equivalency to the EU-approved Suboxone Tablet [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]; in March 2018, the film formulation was not listed as launched in Europe [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]. In October 2018, pre-submission meeting was held with BfArM (rapporteur) and HPRA (co-rapporteur) [&lt;ulink linkID="2089489" linkType="Reference"&gt;2089489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;As of March 2016, the company was planning to file in China in 2016 [&lt;ulink linkID="1755436" linkType="Reference"&gt;1755436&lt;/ulink&gt;]. In July 2016,  filing was expected in 4Q16 [&lt;ulink linkID="1784036" linkType="Reference"&gt;1784036&lt;/ulink&gt;]. In March 2017, a filing for approval was filed by Indivior to launch the sublingual tablet formulation as a class 5.1 imported chemical drug in China [&lt;ulink linkID="1904456" linkType="Reference"&gt;1904456&lt;/ulink&gt;]. In June 2017, a priority review was granted [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;]. In March 2018, regulatory approval in China was still awaited for the tablet formulation [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]; in September 2018, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="2086225" linkType="Reference"&gt;2086225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In May 2007, Suboxone (sublingual tablet) was approved in Canada; the product was launched by Schering-Plough in December 2007 [&lt;ulink linkID="1104943" linkType="Reference"&gt;1104943&lt;/ulink&gt;]. In September 2017, Health Canada approved additional doses of the drug, 12 mg/3 mg and 16 mg/4 mg sublingual tablets [&lt;ulink linkID="2005376" linkType="Reference"&gt;2005376&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, Pre-submission meeting was held with Health Canada for the film formulation approval in Canada. In November 2018, the Supplemental New Drug Submission (SNDS) for film formulation was anticipated in the first quarter of 2019 [&lt;ulink linkID="2089489" linkType="Reference"&gt;2089489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By March 2018, tablet formulations had been launched in South Africa [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, tablet formulations had been launched in Turkey [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, tablet formulations had been launched in Israel [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, an  application  for the film formulation approval was submitted in Isarel [&lt;ulink linkID="2089489" linkType="Reference"&gt;2089489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By March 2018, tablet formulations had been launched in New Zealand [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]. In November 2018, the company was planning for the submission for the film formulation [&lt;ulink linkID="2089489" linkType="Reference"&gt;2089489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, tablet formulations had been launched in Hong Kong [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;By March 2018, tablet formulations had been launched in Taiwan [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, tablet formulations had been launched in Indonesia [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, both the tablet and film formulations of the drug had been launched in Malaysia [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2005, Suboxone (sublingual tablet) was approved in Australia [&lt;ulink linkID="1253546" linkType="Reference"&gt;1253546&lt;/ulink&gt;]. By March 2008, the product had been launched in Australia [&lt;ulink linkID="953672" linkType="Reference"&gt;953672&lt;/ulink&gt;]. In February 2011,   Suboxone sublingual film had been approved in Australia [&lt;ulink linkID="1253552" linkType="Reference"&gt;1253552&lt;/ulink&gt;]; by March 2018, the film formulation had been launched in Australia [&lt;ulink linkID="2016653" linkType="Reference"&gt;2016653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In September 2012, analysis of data by the US Poison Control Centers raised concerns regarding pediatric exposure. The analysis found that Suboxone tablets were associated with significantly higher rates of accidental unsupervised pediatric exposure (7.8 to 8.5 times greater). At that time, Reckitt Benckiser filed a Citizen Petition with the FDA to request  all manufacturers of buprenorphine-containing products for opioid dependence treatment to implement national health safety procedures to reduce the risk of pediatric exposure, including educational campaigns and child-resistant, unit-dosed packaging [&lt;ulink linkID="1326331" linkType="Reference"&gt;1326331&lt;/ulink&gt;], [&lt;ulink linkID="1326332" linkType="Reference"&gt;1326332&lt;/ulink&gt;]. The FDA subsequently denied the Reckitt Benckiser's petition, stating that the petition did not raise valid scientific or regulatory issues associated with the product [&lt;ulink linkID="1386008" linkType="Reference"&gt;1386008&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In January 2010, a randomized, parallel-assignment, open-label, phase IV trial (&lt;ulink linkID="59485" linkType="Protocol"&gt;NCT00955162&lt;/ulink&gt;; BU0902) evaluating the effectiveness of Suboxone in reducing intravenous buprenorphine misuse began in patients (expected n = 270) in France. The primary endpoint was the number of study drug injections per week based on patient diaries. The study completed in May 2011 [&lt;ulink linkID="1253747" linkType="Reference"&gt;1253747&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, a randomized, parallel-assignment, open-label, phase IV trial (&lt;ulink linkID="55222" linkType="Protocol"&gt;NCT00901875&lt;/ulink&gt;; BU0808) began in opiate-dependent patients (expected n = 120) in Taiwan. The primary endpoint was retention in treatment over a 13 week time period. At that time, the trial was estimated to complete in February 2010. The study completed in January 2010 [&lt;ulink linkID="1253724" linkType="Reference"&gt;1253724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, a randomized, double-blind, parallel-assignment, phase IV trial (&lt;ulink linkID="36383" linkType="Protocol"&gt;NCT00605033&lt;/ulink&gt;; P04843, SWITCH) evaluating the transfer of patients from buprenorphine to Suboxone began in patients (expected n = 241) in the UK with opioid dependence. The primary endpoint was response rate assessed at day 7 of the double-blind, double-dummy treatment period. The trial completed in June 2009. A total of 143 and 97 patients who received Suboxone or buprenorphine, respectively, were included in the response rate analysis; the response rates for patients receiving Suboxone or buprenorphine were 83.2 and 88.7%, respectively [&lt;ulink linkID="1253697" linkType="Reference"&gt;1253697&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, a randomized, double-blind, placebo-controlled phase IV trial (&lt;ulink linkID="34424" linkType="Protocol"&gt;NCT00604188&lt;/ulink&gt;; P05042) began in patients (expected n = 188) evaluating the acceptability and safety of Suboxone in heroin users as a replacement therapy for opioid dependency in France. The trial would compare direct induction to Suboxone with induction to &lt;ulink linkID="2695" linkType="Drug"&gt;buprenorphine&lt;/ulink&gt; then transfer to Suboxone. The primary endpoint was responders at day 3. By January 2010, the trial had completed. In December 2010, results from the trial were reported. A total of 93 and 94 patients who received direct Suboxone induction or buprenorphine to Suboxone induction, respectively, were included in the response rate analysis; the response rate at day 3 for both induction approaches was 85%, and the rates of non-responders for direct Suboxone induction and  buprenorphine to Suboxone induction were 8 and 9%, respectively [&lt;ulink linkID="1253623" linkType="Reference"&gt;1253623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, an observational, cohort, prospective trial (&lt;ulink linkID="83866" linkType="Protocol"&gt;NCT00725608&lt;/ulink&gt;; P05444) evaluating the transfer from buprenorphine or other treatment for opioid drug dependence to Suboxone began in patients (expected n = 300) in Austria. The primary endpoint was the retention rate at 6 and 12 months. At that time, the trial was estimated to complete in December 2010. The trial completed in May 2011. In 307 patients enrolled, the retention rate at 6 months was 57.3%, and at 12 months was 45.6% [&lt;ulink linkID="1253735" linkType="Reference"&gt;1253735&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2008, an observational, cohort, prospective, postmarketing surveillance trial (&lt;ulink linkID="83944" linkType="Protocol"&gt;NCT00723749&lt;/ulink&gt;; P05603) began in opioid-dependent patients in whom a substitution therapy with Suboxone was planned or indicated (expected n = 384) in Germany. The primary endpoint was the retention rate at 12 months. By January 2011, the trial had completed. Data showed that the retention rate at 12 months was 59.9%. Drug craving had fallen significantly from 32.3 units on a scale at baseline to 7.1 units at 12 months [&lt;ulink linkID="1253617" linkType="Reference"&gt;1253617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, a 60-patient, uncontrolled, open-label, phase IV study (&lt;ulink linkID="48986" linkType="Protocol"&gt;NCT00684073&lt;/ulink&gt;; P05094) was initiated in France. The objective was to evaluate if opioid-dependent patients on buprenorphine  preferred Suboxone after switching to that therapy. Patients  were to continue their prescribed buprenorphine  dose for the first 2 days of the study, then switch to an equivalent Suboxone dose for days 3, 4 and 5. The primary outcome would be patient assessment of preference using the visual analogue scale. The study was completed in December 2007. In  December 2008, data from the trial were reported. The mean overall preference for buprenorphine on days 1 and 2 were 7.04 and 6.83, respectively, and for Suboxone on days 3, 4 and 5 were 7.38, 6.89 and 7.12, respectively. The difference between treatments (Suboxone minus buprenorphine) estimated by ANCOVA was 0.42 [&lt;ulink linkID="948581" linkType="Reference"&gt;948581&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2014, a randomized, double-blind, parallel group, phase III trial (CTR20140152; RB-CN-10-0013) was initiated in China to compare the efficacy of the sublingual tablet with that of placebo in Chinese subjects (n = 260) with opioid dependence. The trial was also designed to evaluate the safety and tolerability. In December 2015, the trial was completed [&lt;ulink linkID="1908111" linkType="Reference"&gt;1908111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, a non-randomized, open-label, parallel group, phase I trial (CTR20140153; RB-CN-10-0015) was initiated in China to assess the steady state pharmacokinetics of buprenorphine, norbuprenorphine and naloxone after 9-day continuous administration of single dose a day in opioid-dependent patients (n = 25) receiving withdrawal treatment. The trial was also designed to evaluate the safety and tolerability of multiple administrations. In November 2015, the trial was completed [&lt;ulink linkID="1908110" linkType="Reference"&gt;1908110&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2015 the RB-CN-10-001 trial was ongoing to evaluate the product in Chinese subjects [&lt;ulink linkID="1650527" linkType="Reference"&gt;1650527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, a non-randomized, open-label, single-arm, phase I trial (CTR20132963; RB-CN-10-0012) was initiated in China to evaluate the PK characteristics of the sublingual tablet in Chinese healthy subjects (n = 82). The trial was also designed to assess the safety and tolerability of the drug in healthy subjects blocked by naloxone. In April 2014, the trial was completed [&lt;ulink linkID="1908109" linkType="Reference"&gt;1908109&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a randomized, double-blind, crossover-assignment, pharmacodynamic phase III trial (&lt;ulink linkID="83949" linkType="Protocol"&gt;NCT00710385&lt;/ulink&gt;; 5518) comparing the abuse liabilities of intravenous buprenorphine and Suboxone in individuals who were physically dependent on sublingual buprenorphine (expected n = 12) began in the US. The primary endpoint was the progressive ratio breakpoint value. The trial completed in August 2008 [&lt;ulink linkID="1253757" linkType="Reference"&gt;1253757&lt;/ulink&gt;]. In April 2010, results from the trial were published. The intravenous self-administration of Suboxone was significantly less frequent than buprenorphine or heroin. Intravenous self-administration was more likely to be observed in patients maintained on the lowest sublingual buprenorphine dose. Significantly lower subjective ratings of 'drug liking' and 'desire to take the drug again' were reported for Suboxone compared with buprenorphine or heroin [&lt;ulink linkID="1253955" linkType="Reference"&gt;1253955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2006, results were reported for a 1-year clinical trial in opiate-dependent patients, comprising a 4-week randomized, double-blinded comparison of Suboxone, &lt;ulink linkID="2695" linkType="Drug"&gt;buprenorphine&lt;/ulink&gt; monotherapy and placebo followed by a 48-week safety study of Suboxone. Suboxone demonstrated similar efficacy and safety to buprenorphine, with a significantly higher percentage of urine samples testing negative for non-study opioids for both Suboxone versus placebo and buprenorphine versus placebo. The reported adverse events during the study for Suboxone were similar to those seen with buprenorphine monotherapy and included those generally seen with other opioid-agonist treatments (headache, withdrawal syndrome and insomnia) [&lt;ulink linkID="680734" linkType="Reference"&gt;680734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the International Narcotics Research 31st Conference (Seattle, WA), in July 2000, the National Institute on Drug Abuse reported that in clinical trials, 50% of patients on 8-mg doses of buprenorphine gave opiate-free urine samples for over 1 year. In shorter-term trials with buprenorphine versus methadone, 32% of patients on an 8-mg dose of buprenorphine gave 12 consecutive opiate-free urine samples, while 19% of methadone users gave all opiate-free urine samples over the same 1-month period. The naloxone/buprenorphine (1:8 mg) combination was similarly effective, but was rated as 'less desirable' by treated individuals [&lt;ulink linkID="378300" linkType="Reference"&gt;378300&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, a confirmatory trial application was filed with the SFDA; in August 2012, the application was approved [&lt;ulink linkID="1342686" linkType="Reference"&gt;1342686&lt;/ulink&gt;], [&lt;ulink linkID="1415191" linkType="Reference"&gt;1415191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In March 2015, clinical data were presented from 43 subjects at the 116th ASCPT Annual Meeting in New Orleans, LA. Subjects with mild, moderate and severe hepatic impairment and those with HCV, but without hepatic impairment and subjects with normal hepatic impairment received single dose of suboxone (2.0/0.5 of buprenorphine/naloxone) tablet under fasting conditions. Overall, exposures of naloxone were increased significantly with hepatic impairment  (HI) and to a lesser extent of buprenorphine. The combination of buprenorphine/naloxone should be avoided in patients with severe HI and moderate HI [&lt;ulink linkID="1638490" linkType="Reference"&gt;1638490&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="RO">Romania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-03-31T00:00:00.000Z</StatusDate><Source id="953672" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-31T00:00:00.000Z</StatusDate><Source id="1253294" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1172264" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="BA">Bosnia and Herzegovina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="MT">Malta</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1172264" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016653" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1082975">Indivior plc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-13T00:00:00.000Z</StatusDate><Source id="1904456" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1172264" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1172264" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29074">Reckitt Benckiser plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-06-07T00:00:00.000Z</StatusDate><Source id="1253322" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-08-10T00:00:00.000Z</StatusDate><Source id="1253317" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-09-26T00:00:00.000Z</StatusDate><Source id="1253345" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="1104943" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-27T00:00:00.000Z</StatusDate><Source id="1253546" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-11T00:00:00.000Z</StatusDate><Source id="1104943" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-11-03T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-11-30T00:00:00.000Z</StatusDate><Source id="1253962" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-11-03T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1253724" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-20T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-22T00:00:00.000Z</StatusDate><Source id="1908109" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29074">Reckitt Benckiser plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-22T00:00:00.000Z</StatusDate><Source id="1908111" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29074">Reckitt Benckiser plc</OwnerCompany><Country id="US">US</Country><Indication id="243">Opiate dependence</Indication><AwardedIndication>Treatment of opiate addiction in opiate users</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-10-27T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1082975">Indivior plc</OwnerCompany><Country id="CN">China</Country><Indication id="243">Opiate dependence</Indication><AwardedIndication>Treatment of opiate addiction in opiate users</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-06T00:00:00.000Z</MileStoneDate><Source id="2005376" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01193"><Name>Opioid receptor kappa</Name><SwissprotNumbers><Swissprot>P33534</Swissprot><Swissprot>P34975</Swissprot><Swissprot>P41144</Swissprot><Swissprot>P41145</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01361"><Name>Opioid receptor mu</Name><SwissprotNumbers><Swissprot>P33535</Swissprot><Swissprot>P35372</Swissprot><Swissprot>P42866</Swissprot><Swissprot>P79350</Swissprot><Swissprot>P97266</Swissprot><Swissprot>Q5IS39</Swissprot><Swissprot>Q95247</Swissprot><Swissprot>Q95M54</Swissprot><Swissprot>Q9MYW9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2147453" linkType="reference" linkID="2147453"&gt;2147453&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1008765">Aquestive Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1014560">Zhejiang Pukang Biotechnology Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1027030">Amneal Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1032454">Aoxing Pharmaceutical Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1033677">American Oriental Bioengineering Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1082975">Indivior plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1085756">Mallinckrodt plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29074">Reckitt Benckiser plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3Cc6c5c(c(cc6)O)O4)CC7CC7)OC)(C(C)(C)C)O</Smiles><Smiles>C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3Cc6c5c(c(cc6)O)O4)CC7CC7)OC)(C(C)(C)C)O.Cl</Smiles><Smiles>C=CCN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O</Smiles></StructureSmiles><Deals><Deal id="111738" title="Schering-Plough to distribute Reckitt &amp; Colman's buprenorphine worldwide excluding Japan, Taiwan and Korea "></Deal><Deal id="123704" title="Adams to license MonoSolRx's edible film drug delivery technology for the development of respiratory drugs in North America"></Deal><Deal id="133957" title="MonoSol to manufacture and supply Reckitt Benckiser's Suboxone film   "></Deal><Deal id="146744" title="Mallinckrodt to distribute generic Suboxone from Amneal"></Deal><Deal id="170824" title="Narcotics and pain management products in China &amp; $18M equity investment for 38% stake"></Deal><Deal id="253204" title="Zhejiang Pukang to acquire Indivior's Sai Bo Song (buprenorphine, naloxone) tablet for opiate dependence in China"></Deal><Deal id="253952" title="Sandoz to market authorized generic version of Suboxone for Indivior in the US"></Deal></Deals><PatentFamilies><PatentFamily id="1053429" number="EP-00319243" title="Pharmaceutical Compositions"></PatentFamily><PatentFamily id="1086419" number="WO-03030881" title="Glucan based film delivery systems"></PatentFamily><PatentFamily id="1218906" number="WO-2006031209" title="Polyethylene oxide-based films and drug delivery systems made therefrom"></PatentFamily><PatentFamily id="1399182" number="WO-2007030754" title="Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions"></PatentFamily><PatentFamily id="1471491" number="WO-2008104737" title="Improved medicinal compositions comprising buprenorphine and naloxone"></PatentFamily><PatentFamily id="1679173" number="WO-2004066986" title="Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom"></PatentFamily><PatentFamily id="2292727" number="WO-2008104738" title="Improvements in and relating to medicinal compositions"></PatentFamily><PatentFamily id="2798401" number="WO-2014144241" title="Sublingual and buccal film compositions"></PatentFamily><PatentFamily id="2813096" number="WO-2014168925" title="Compositions to alleviate presystemic metabolism of opioids"></PatentFamily><PatentFamily id="519773" number="WO-2011017483" title="Sublingual and buccal film compositions"></PatentFamily><PatentFamily id="593791" number="WO-2011017484" title="Sublingual and buccal film compositions"></PatentFamily><PatentFamily id="756707" number="EP-00144243" title="Analgesic compositions"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aquestive Therapeutics Inc" id="1008765"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Midatech Pharma PLC" id="1011432"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amneal Pharmaceuticals Inc" id="1027030"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IntelGenx Technologies Corp" id="1030619"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KemPharm Inc" id="1038304"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alvogen Inc" id="1051273"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Altria Client Services Inc" id="1072753"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Indivior plc" id="1082975"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mallinckrodt plc" id="1085756"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Morgan Stanley Senior Funding Inc" id="1154410"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>5</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Denko Corp" id="18574"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Virginia Commonwealth University" id="20696"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioDelivery Sciences International Inc" id="21164"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Reckitt Benckiser plc" id="29074"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>5</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>